Published in Vaccine Weekly, February 28th, 2007
The study was a double-blind, placebo-controlled clinical trial conducted with 72 participants with mild to moderate hypertension. It was designed to evaluate safety, tolerability, and exploratory efficacy of two dose levels of the vaccine . For efficacy evaluation, the change in blood pressure from baseline to post-treatment was assessed in individual subjects by 24-hour ambulatory blood pressure monitoring.
Treatment with CYT006-AngQb was safe and very well tolerated. The majority of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.